Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Identifieur interne : 001250 ( PubMed/Corpus ); précédent : 001249; suivant : 001251Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Auteurs : Roberto Sorio ; Célia Roemer-Becuwe ; Felix Hilpert ; Emma Gibbs ; Yolanda García ; Janne Kaern ; Manon Huizing ; Petronella Witteveen ; Flora Zagouri ; David Coeffic ; Hans-Joachim Lück ; Antonio González-Martín ; Gunnar Kristensen ; Charles-Briac Levaché ; Chee Khoon Lee ; Val Gebski ; Eric Pujade-LauraineSource :
- Gynecologic oncology [ 1095-6859 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bevacizumab (administration & dosage), Bevacizumab (adverse effects), Disease-Free Survival, Doxorubicin (administration & dosage), Doxorubicin (analogs & derivatives), Drug Resistance, Neoplasm, Female, Humans, Hypertension (chemically induced), Hypertension (physiopathology), Middle Aged, Neoplasm Recurrence, Local (drug therapy), Ovarian Neoplasms (drug therapy), Paclitaxel (administration & dosage), Patient Selection, Platinum Compounds, Polyethylene Glycols (administration & dosage), Topotecan (administration & dosage).
- MESH :
- chemical , administration & dosage : Bevacizumab, Doxorubicin, Paclitaxel, Polyethylene Glycols, Topotecan.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Bevacizumab.
- chemical , analogs & derivatives : Doxorubicin.
- chemically induced : Hypertension.
- drug therapy : Neoplasm Recurrence, Local, Ovarian Neoplasms.
- physiopathology : Hypertension.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Age Factors, Aged, Aged, 80 and over, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Patient Selection, Platinum Compounds.
Abstract
The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).
DOI: 10.1016/j.ygyno.2016.11.006
PubMed: 27871723
Links to Exploration step
pubmed:27871723Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.</title><author><name sortKey="Sorio, Roberto" sort="Sorio, Roberto" uniqKey="Sorio R" first="Roberto" last="Sorio">Roberto Sorio</name><affiliation><nlm:affiliation>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN, Italy. Electronic address: rsorio@cro.it.</nlm:affiliation></affiliation></author><author><name sortKey="Roemer Becuwe, Celia" sort="Roemer Becuwe, Celia" uniqKey="Roemer Becuwe C" first="Célia" last="Roemer-Becuwe">Célia Roemer-Becuwe</name><affiliation><nlm:affiliation>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gibbs, Emma" sort="Gibbs, Emma" uniqKey="Gibbs E" first="Emma" last="Gibbs">Emma Gibbs</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia, Yolanda" sort="Garcia, Yolanda" uniqKey="Garcia Y" first="Yolanda" last="García">Yolanda García</name><affiliation><nlm:affiliation>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kaern, Janne" sort="Kaern, Janne" uniqKey="Kaern J" first="Janne" last="Kaern">Janne Kaern</name><affiliation><nlm:affiliation>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Huizing, Manon" sort="Huizing, Manon" uniqKey="Huizing M" first="Manon" last="Huizing">Manon Huizing</name><affiliation><nlm:affiliation>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Witteveen, Petronella" sort="Witteveen, Petronella" uniqKey="Witteveen P" first="Petronella" last="Witteveen">Petronella Witteveen</name><affiliation><nlm:affiliation>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Zagouri, Flora" sort="Zagouri, Flora" uniqKey="Zagouri F" first="Flora" last="Zagouri">Flora Zagouri</name><affiliation><nlm:affiliation>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Coeffic, David" sort="Coeffic, David" uniqKey="Coeffic D" first="David" last="Coeffic">David Coeffic</name><affiliation><nlm:affiliation>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Luck, Hans Joachim" sort="Luck, Hans Joachim" uniqKey="Luck H" first="Hans-Joachim" last="Lück">Hans-Joachim Lück</name><affiliation><nlm:affiliation>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Martin, Antonio" sort="Gonzalez Martin, Antonio" uniqKey="Gonzalez Martin A" first="Antonio" last="González-Martín">Antonio González-Martín</name><affiliation><nlm:affiliation>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Levache, Charles Briac" sort="Levache, Charles Briac" uniqKey="Levache C" first="Charles-Briac" last="Levaché">Charles-Briac Levaché</name><affiliation><nlm:affiliation>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27871723</idno><idno type="pmid">27871723</idno><idno type="doi">10.1016/j.ygyno.2016.11.006</idno><idno type="wicri:Area/PubMed/Corpus">001250</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001250</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.</title><author><name sortKey="Sorio, Roberto" sort="Sorio, Roberto" uniqKey="Sorio R" first="Roberto" last="Sorio">Roberto Sorio</name><affiliation><nlm:affiliation>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN, Italy. Electronic address: rsorio@cro.it.</nlm:affiliation></affiliation></author><author><name sortKey="Roemer Becuwe, Celia" sort="Roemer Becuwe, Celia" uniqKey="Roemer Becuwe C" first="Célia" last="Roemer-Becuwe">Célia Roemer-Becuwe</name><affiliation><nlm:affiliation>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gibbs, Emma" sort="Gibbs, Emma" uniqKey="Gibbs E" first="Emma" last="Gibbs">Emma Gibbs</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia, Yolanda" sort="Garcia, Yolanda" uniqKey="Garcia Y" first="Yolanda" last="García">Yolanda García</name><affiliation><nlm:affiliation>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kaern, Janne" sort="Kaern, Janne" uniqKey="Kaern J" first="Janne" last="Kaern">Janne Kaern</name><affiliation><nlm:affiliation>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Huizing, Manon" sort="Huizing, Manon" uniqKey="Huizing M" first="Manon" last="Huizing">Manon Huizing</name><affiliation><nlm:affiliation>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Witteveen, Petronella" sort="Witteveen, Petronella" uniqKey="Witteveen P" first="Petronella" last="Witteveen">Petronella Witteveen</name><affiliation><nlm:affiliation>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Zagouri, Flora" sort="Zagouri, Flora" uniqKey="Zagouri F" first="Flora" last="Zagouri">Flora Zagouri</name><affiliation><nlm:affiliation>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Coeffic, David" sort="Coeffic, David" uniqKey="Coeffic D" first="David" last="Coeffic">David Coeffic</name><affiliation><nlm:affiliation>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Luck, Hans Joachim" sort="Luck, Hans Joachim" uniqKey="Luck H" first="Hans-Joachim" last="Lück">Hans-Joachim Lück</name><affiliation><nlm:affiliation>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Martin, Antonio" sort="Gonzalez Martin, Antonio" uniqKey="Gonzalez Martin A" first="Antonio" last="González-Martín">Antonio González-Martín</name><affiliation><nlm:affiliation>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Levache, Charles Briac" sort="Levache, Charles Briac" uniqKey="Levache C" first="Charles-Briac" last="Levaché">Charles-Briac Levaché</name><affiliation><nlm:affiliation>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bevacizumab (administration & dosage)</term><term>Bevacizumab (adverse effects)</term><term>Disease-Free Survival</term><term>Doxorubicin (administration & dosage)</term><term>Doxorubicin (analogs & derivatives)</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Hypertension (chemically induced)</term><term>Hypertension (physiopathology)</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Ovarian Neoplasms (drug therapy)</term><term>Paclitaxel (administration & dosage)</term><term>Patient Selection</term><term>Platinum Compounds</term><term>Polyethylene Glycols (administration & dosage)</term><term>Topotecan (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bevacizumab</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term><term>Topotecan</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Bevacizumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Doxorubicin</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Patient Selection</term><term>Platinum Compounds</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27871723</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>22</Day></DateCreated><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Gynecologic oncology</Title><ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.</ArticleTitle><Pagination><MedlinePgn>65-71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0090-8258(16)31562-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2016.11.006</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with PROC were randomised to receive investigator-selected single-agent chemotherapy alone or with bevacizumab. Post-hoc exploratory analyses assessed efficacy, safety and patient-reported outcomes according to age <65 versus ≥65years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the 133 patients (37%) aged ≥65years, baseline hypertension was more frequent and ascites was less common than in patients <65years. The magnitude of PFS benefit from bevacizumab was similar in patients ≥65 versus <65years (hazard ratio 0.44 [95% CI, 0.31-0.64] versus 0.49 [95% CI, 0.37-0.64], respectively, treatment-age interaction p=0.58), with similar improvements in response rates. Grade≥3 hypertension was more common with bevacizumab than chemotherapy alone in both subgroups, and more common in older than younger patients irrespective of treatment. However, there was no excess of other adverse events of specific interest for bevacizumab, including venous thromboembolic events, in older patients. More patients receiving bevacizumab in the younger but not the older subgroup showed improved gastrointestinal/abdominal symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In exploratory analyses, PFS and response rate improvement with bevacizumab were consistent in older and younger patients. Grade≥3 hypertension was more common in elderly bevacizumab-treated patients; careful monitoring is recommended. Overall, bevacizumab-containing therapy was well tolerated in a selected population aged ≥65years, suggesting a favourable benefit:risk profile. However, geriatric assessments are needed to improve selection of elderly patients potentially gaining symptom and quality of life improvements from bevacizumab-containing therapy.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.govNCT00976911.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorio</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN, Italy. Electronic address: rsorio@cro.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roemer-Becuwe</LastName><ForeName>Célia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilpert</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaern</LastName><ForeName>Janne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huizing</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witteveen</LastName><ForeName>Petronella</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagouri</LastName><ForeName>Flora</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coeffic</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lück</LastName><ForeName>Hans-Joachim</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Martín</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levaché</LastName><ForeName>Charles-Briac</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chee Khoon</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebski</LastName><ForeName>Val</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AURELIA Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00976911</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gynecol Oncol</MedlineTA><NlmUniqueID>0365304</NlmUniqueID><ISSNLinking>0090-8258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017671">Platinum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506643">liposomal doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>7M7YKX2N15</RegistryNumber><NameOfSubstance UI="D019772">Topotecan</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017671" MajorTopicYN="N">Platinum Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019772" MajorTopicYN="N">Topotecan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bevacizumab</Keyword><Keyword MajorTopicYN="Y">Elderly</Keyword><Keyword MajorTopicYN="Y">Ovarian cancer</Keyword><Keyword MajorTopicYN="Y">Patient-reported outcomes</Keyword><Keyword MajorTopicYN="Y">Platinum resistant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27871723</ArticleId><ArticleId IdType="pii">S0090-8258(16)31562-1</ArticleId><ArticleId IdType="doi">10.1016/j.ygyno.2016.11.006</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001250 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001250 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27871723
|texte= Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27871723" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |